Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cybin Inc. Common Shares (NY:CYBN)

7.940 +0.560 (+7.59%)
Official Closing Price Updated: 5:00 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 442,098
Open 7.950
Bid (Size) 7.890 (1)
Ask (Size) 8.030 (35)
Prev. Close 7.380
Today's Range 7.550 - 7.970
52wk Range 4.810 - 13.88
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Secures $50 Million in Convertible Debenture Financing from High Trail
Via Investor Brand Network
Topics Intellectual Property
REPEAT/Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures
From Cybin Inc.
Via Business Wire

Performance

YTD
-15.6%
-15.6%
1 Month
-10.0%
-10.0%
3 Month
+54.2%
+54.2%
6 Month
-25.4%
-25.4%
1 Year
-21.0%
-21.0%

More News

Read More
Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures
Via FinancialNewsMedia
Topics Intellectual Property
Global Neuro-Psychiatric Disorders & Treatment Market Projected to Reach $166 Billion by 2032
Via FinancialNewsMedia
Topics Death
Cybin Reports Fiscal Year 2025 Financial Results and Recent Business Highlights
From Cybin Inc.
Via Business Wire
Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Highlights Progress on Phase 3 Psychedelic Therapeutics Program
Via Investor Brand Network
Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics
From Cybin Inc.
Via Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO to Speak at H.C. Wainwright Neuro Perspectives Conference
Via Investor Brand Network
Cybin to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Conference
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO to Speak on Pivotal Trials Panel at Psychedelic Science 2025
Via Investor Brand Network
Cybin to Participate in the 2025 Psychedelic Science Conference
From Cybin Inc.
Via Business Wire
Psychedelics Policy Is Shifting In Washington: Here's What One Biotech CEO Sees Coming
Via Benzinga
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Secures U.S. Patent for CYB004 Anxiety Treatment Candidate
Via Investor Brand Network
Topics Intellectual Property
Cybin Announces Additional U.S. Patent Supporting its CYB004 Program in Phase 2 Development for Generalized Anxiety Disorder
From Cybin Inc.
Via Business Wire
Ex-Gov't Foe Joins Trump, RFK Jr.'s HHS To Lead Psychedelics Policy: What It Means For Investors
Via Benzinga
Topics Government
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO to Discuss Phase 3 Progress and Industry Trends in May 29 Fireside Chat
Via Investor Brand Network
Cybin to Participate in Water Tower Research Fireside Chat on May 29, 2025
From Cybin Inc.
Via Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Applauds FDA Support for Psychedelic Therapeutics, Advances Phase 3 Trials
Via Investor Brand Network
Cybin Applauds FDA Commissioner Dr. Martin Makary’s Call to Accelerate and Prioritize Research on Psychedelic Therapeutics
From Cybin Inc.
Via Business Wire
InvestorkNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Taps Thermo Fisher for Phase 3 and Commercial Production of CYB003
Via Investor Brand Network
Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for its CYB003 Program for the Adjunctive Treatment of Major Depressive Disorder
From Cybin Inc.
Via Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Present at Alliance Global Partners Healthcare Showcase on May 21
Via Investor Brand Network
Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Secures U.S. Patent for CYB003 Depression Treatment
Via Investor Brand Network
Topics Intellectual Property

Frequently Asked Questions

Is Cybin Inc. Common Shares publicly traded?
Yes, Cybin Inc. Common Shares is publicly traded.
What exchange does Cybin Inc. Common Shares trade on?
Cybin Inc. Common Shares trades on the New York Stock Exchange
What is the ticker symbol for Cybin Inc. Common Shares?
The ticker symbol for Cybin Inc. Common Shares is CYBN on the New York Stock Exchange
What is the current price of Cybin Inc. Common Shares?
The current price of Cybin Inc. Common Shares is 7.940
When was Cybin Inc. Common Shares last traded?
The last trade of Cybin Inc. Common Shares was at 07/03/25 05:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.